Pharmacological Correlation between Total Drug Concentration and Lactones of CPT‐11 and SN‐38 in Patients Treated with CPT‐11

Japanese Journal of Cancer Research

Volumn 86, Issue 1, 1995, Pages 111-116

  Sasaki, Yasutsuna ^a   Yoshida, Yasushi ^b   Sudoh, Kenichi ^b   Hakusui, Hideo ^b   Fujii, Hirofumi ^a   Ohtsu, Tomoko ^a   Wakita, Hisashi ^a   Igarashi, Tadahiko ^a   Itoh, Kuniaki ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

CPT 11; Lactone; Pharmacokinetics; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CARBOXYLIC ACID DERIVATIVE; DRUG METABOLITE; IRINOTECAN; LACTONE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; KINETICS; LACTONES; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 0028843263     PISSN: 09105050     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1995.tb02995.x     Document Type: Article

References (40)

1. Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibition from Camptotheca accuminata
2. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC‐100880)
3. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC‐100880): correlation with preclinical studies
4. Antitumor activity of 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino]carbonyloxycamptothecin, a novel water‐soluble derivative of camptothecin, against murine tumors
5. Antitumor effect of CPT‐11, a new derivative of camptothecin, against pleiotropic drug‐resistant tumors in vitro and in vivo
6. Metabolism and pharmacokinetics of the camptothecin analogue CPT‐11 in the mouse
7. CPT‐11 converting enzyme from rat serum: purification and some properties
8. The current status of camptothecin analogues as antitumor agents
9. Phase I study of weekly intravenous infusion of CPT‐11, a new derivative of camptothecin, in the treatment of advanced non‐small‐cell lung cancer
10. Phase I study and pharmacokinetics of CPT‐11 with 5‐day continuous infusion
11. A pharmacokinetic and pharmacodynamic analysis of CPT‐11 and its active metabolite SN‐38
12. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity
13. Kinetics of ring opening of camptothecin analogues and topotecan in plasma and whole blood
14. Pharmacokinetics of closed lactone and open‐ring CPT‐11 in dog
15. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer
16. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor
17. Phase I and pharmacokinetic trial of weekly CPT‐11
18. Phase I and pharmacological study of novel topoisomerase I inhibitor 7‐ethyl‐10‐[4‐(1‐piperidino)‐ 1 ‐piperidino] carbonyloxycamptothecin (CPT‐11) administered as a ninety‐minute infusion every 3 weeks
19. Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibition from Camptotheca accuminata
20. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC‐100880)
21. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC‐100880): correlation with preclinical studies
22. Antitumor activity of 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino]carbonyloxycamptothecin, a novel water‐soluble derivative of camptothecin, against murine tumors
23. Antitumor effect of CPT‐11, a new derivative of camptothecin, against pleiotropic drug‐resistant tumors in vitro and in vivo
24. Metabolism and pharmacokinetics of the camptothecin analogue CPT‐11 in the mouse
25. CPT‐11 converting enzyme from rat serum: purification and some properties
26. The current status of camptothecin analogues as antitumor agents
27. Phase I study of weekly intravenous infusion of CPT‐11, a new derivative of camptothecin, in the treatment of advanced non‐small‐cell lung cancer
28. Phase I study and pharmacokinetics of CPT‐11 with 5‐day continuous infusion
29. A pharmacokinetic and pharmacodynamic analysis of CPT‐11 and its active metabolite SN‐38
30. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity
31. Kinetics of ring opening of camptothecin analogues and topotecan in plasma and whole blood
32. Pharmacokinetics of closed lactone and open‐ring CPT‐11 in dog
33. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer
34. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor
35. Phase I and pharmacokinetic trial of weekly CPT‐11
36. Phase I and pharmacological study of novel topoisomerase I inhibitor 7‐ethyl‐10‐[4‐(1‐piperidino)‐ 1 ‐piperidino] carbonyloxycamptothecin (CPT‐11) administered as a ninety‐minute infusion every 3 weeks